Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02423863
Recruitment Status : Recruiting
First Posted : April 22, 2015
Last Update Posted : November 13, 2019
National Institutes of Health (NIH)
Icahn School of Medicine at Mount Sinai
Bay Hematology Oncology
National Cancer Institute (NCI)
University of Missouri-Columbia
Chevy Chase Regional Cancer Care Associates LLC
Dermatologic Surgery Center of Washington LLC and Skin Cancer Treatment Center
Information provided by (Responsible Party):
Oncovir, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : December 2021

Publications automatically indexed to this study by Identifier (NCT Number):